Research desk · EXEL · Nasdaq
EXEL Stock
SEC financials, peer compare, and chart. Scores open the matching desk. Research only — not advice.
Exelixis Inc · Biological Products, (No Diagnostic Substances)
Exelixis Inc financial statements, chart, and peer compare from SEC filings.
Exelixis Inc (EXEL) develops biotechnology and life-science products.
- Market cap
- $13.58B
- P/E
- 17.77
- Op. margin
- 40.91%
- Profit margin
- 34.04%
- FCF margin
- 21.17%
- ROE
- 45.68%
Related Health Care stocks: UTHR stock financials · NBIX stock financials · RPRX stock financials · SRPT stock financials · MRNA stock financials
EXEL financial statements
Each Compare name is its own block of years. Filing lines are SEC reports; P/E and price sit on that name’s TTM column only.
EXEL stock peer compare
Each bar is that name’s percent vs its last TTM, on one zero line. Zero is unchanged. This ticker is the black bar.
Focus chart
Zero is unchanged vs last TTM. Every name is a percent for the metric you pick.
EXEL stock peer headlines
Yahoo Finance RSS for EXEL and the names in Compare.
| Ticker | Date | Headline |
|---|---|---|
| Loading headlines… | ||
EXEL stock price chart
Overlays follow the Compare table.
EXEL stock — research snapshot
Screen strengths and watchouts for EXEL stock from the latest Misprise snapshot.
Strengths
- ROA 33.8% — strong returns on assets.
- ROE 45.7% — efficient equity returns.
- Operating margin 40.9% — solid operating leverage.
- Profit margin 34.0% — durable bottom-line quality.
- FCF margin 21.2% — cash conversion looks healthy.
Watchouts
- No major red flags on the core screen — still read the filings on your own.
- Rev CAGR 5Y 18.6%
- Rev CAGR 3Y 8.2%
- EPS CAGR 5Y 51.4%
- EPS CAGR 3Y 62.3%
- FCF CAGR 5Y 37.4%
- FCF CAGR 3Y 44.1%
EXEL stock FAQs
Short answers for EXEL stock — statements, sector, and how this page is meant to be used.
What is EXEL stock?
Exelixis Inc (EXEL) develops biotechnology and life-science products. EXEL stock sits in Health Care (Biological Products, (No Diagnostic Substances)), listed on Nasdaq.
Where can I find Exelixis Inc financial statements?
Exelixis Inc financial statements — income statement, balance sheet, and cash flow — are on this EXEL stock page, parsed from SEC 10-K and 10-Q filings. Use Annual or Quarterly, then the statement tabs. Research only.
What happened to EXEL stock?
This page is a research snapshot of Exelixis Inc (EXEL) from the latest SEC filings in the Misprise database as of TTM. It is not a news feed or a delisting notice. Open the financial statements, chart, and peer compare below, then read the filings. Research only — not financial advice.
Does this page show the EXEL stock price?
The live chart on this EXEL stock page is the same TradingView chart as the screener. Statement tables use SEC filings. Any price or multiple on the TTM column is a market snapshot from the last seed, not a real-time quote. Research only.
What sector is EXEL stock in?
Exelixis Inc is classified in Biological Products, (No Diagnostic Substances), inside the Health Care sector, and trades on Nasdaq. This page is a research snapshot, not a full company profile.
How do I read EXEL financial statements?
Start with this ticker’s block (TTM, then its fiscal years or quarters). Each Compare name is a separate block of its own periods — not mixed by year. A blank is a period we do not have, not a zero. Research only — not a buy or sell.
Where does the EXEL statement data come from?
Income, balance sheet, and cash-flow lines are parsed from SEC company filings (10-K / 10-Q and 20-F). TTM is the last four reported quarters added together, not a separate filing. P/E, forward P/E, price, and market cap are a market quote at last seed — trailing P/E from the quote when available, otherwise last price divided by TTM EPS. They are not 10-K line items and appear on the TTM column only. Research only — not financial advice.
Where can I find the EXEL income statement, balance sheet, and cash flow?
On this EXEL stock page, open Financial statements and use the Income, Balance sheet, and Cash flow tabs. Growth and valuation sit under More. Filing figures are from SEC reports; valuation multiples are the market snapshot described above.
What is the Misprise Score for EXEL stock?
EXEL stock currently scores 72/100 (Constructive (60–72)). Exelixis Inc is constructive on the screen — worth a deeper look at compounding and filings before treating it as high conviction. The score is a screen of quality, growth, and balance-sheet inputs — not a price target. Compare it in the Misprise screener; it is not a separate score page.
How is the EXEL comparison winner decided?
Lead and Tie follow the number printed on each factor row, not a blended category score. Growth, quality, score, current ratio, and coverage: the higher figure leads. Value multiples (P/E, PEG, P/B, P/S) and debt ratios: the lower figure leads. Tie appears only when those printed numbers match. The header winner is whoever takes more of those five rows. CAGR uses the 5-year horizon and drops to 3-year only when both names report it. Research only — not a buy or sell.
What is the Anomaly Score on this EXEL page?
Anomaly Score is how unusual a filing pattern is versus this company’s own history and its industry — not the same as Misprise Score. A high anomaly with a weak Misprise Score is often a noisy name. Open the anomaly detector to see the flag. Research only — not financial advice.
What does the green grant dot mean on EXEL stock?
A green circle next to the title means this ticker appears in the Misprise grants calendar with a recent federal award (USASpending / SAM). Tap the dot for date, agency, and amount when available. It is a research flag only — not a buy or sell signal.
Is EXEL stock a buy?
No recommendation either way. This EXEL stock page organizes statements, ratios, and peers so you can do your own work. It is educational only — not advice to buy or sell Exelixis Inc.